Augusta University — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications4liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ATHENA — Assessing Treatment With High-phenolic EVOO Supplements for Neurovascular ActivityThe goal of this clinical trial is to determine whether the extra-virgin olive oil (EVOO) phenolic dietary supplement can improve memory function and modulate biomarkers among individuals with mild cognitive impairment (MCI). The main questions it aims to answer are: * Does dietary supplementation with EVOO phenolics improve cognitive function? * What would be the effect of the EVOO dietary supplement on other MCI-related biomarkers, including vascular function and biological pathways? Researchers will compare the EVOO dietary supplements with a placebo (a look-alike substance that contains no EVOO phenolics) Participants will: * Take EVOO dietary supplements or a placebo daily for 6 months * Visit the study site during the 6-month study for screening and testing.	Alzheimer	Non applicable	À vérifier	United States	À vérifier
PrazosinHigh blood pressure, or hypertension, is a serious problem in the African-American (AA) population which affects nearly 7 of every 10 AAs in our area. Previously the investigators showed that a significant number of AAs held onto or retained salt during mental stress (sodium retainers). The investigators believe that the increased salt load and resulting blood pressure load contributes to the eventual development of hypertension in these individuals. The purpose of this study is to find out if this response is due to the direct stimulation of the kidney (the organ that controls salt levels in the body, by the brain). To do this, the investigators will determine if a drug that stops the connection between the brain and the kidney during mental stress will prevent sodium retention in sodium retainers. Prazosin is an alpha adrenergic receptor blocker that has been approved by the Food and Drug Administration (FDA). None of the subjects who participate in this study have high blood pressure. The subjects will not know which testing week is the drug week and which is the placebo week.	Hypertension	Phase 2	À vérifier	United States	À vérifier
PrazosinHigh blood pressure, or hypertension, is a serious problem in the African-American (AA) population which affects nearly 7 of every 10 AAs in our area. Previously the investigators showed that a significant number of AAs held onto or retained salt during mental stress (sodium retainers). The investigators believe that the increased salt load and resulting blood pressure load contributes to the eventual development of hypertension in these individuals. The purpose of this study is to find out if this response is due to the direct stimulation of the kidney (the organ that controls salt levels in the body, by the brain). To do this, the investigators will determine if a drug that stops the connection between the brain and the kidney during mental stress will prevent sodium retention in sodium retainers. Prazosin is an alpha adrenergic receptor blocker that has been approved by the Food and Drug Administration (FDA). None of the subjects who participate in this study have high blood pressure. The subjects will not know which testing week is the drug week and which is the placebo week.	Hypertension	Phase 2	À vérifier	United States	À vérifier
ATHENA — Assessing Treatment With High-phenolic EVOO Supplements for Neurovascular ActivityThe goal of this clinical trial is to determine whether the extra-virgin olive oil (EVOO) phenolic dietary supplement can improve memory function and modulate biomarkers among individuals with mild cognitive impairment (MCI). The main questions it aims to answer are: * Does dietary supplementation with EVOO phenolics improve cognitive function? * What would be the effect of the EVOO dietary supplement on other MCI-related biomarkers, including vascular function and biological pathways? Researchers will compare the EVOO dietary supplements with a placebo (a look-alike substance that contains no EVOO phenolics) Participants will: * Take EVOO dietary supplements or a placebo daily for 6 months * Visit the study site during the 6-month study for screening and testing.	Alzheimer	Non applicable	À vérifier	United States	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
ATHENA — Assessing Treatment With High-phenolic EVOO Supplements for Neurovascular Activity	Alzheimer	Non applicable	NCT07741773	ATHENA — Assessing Treatment With High-phenolic EVOO Supplements for Neurovascular Activity	NOT_YET_RECRUITING
Prazosin	Hypertension	Phase 2	NCT02431936	Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress	COMPLETED

Publications

4

Molécule	Indication / population	Titre	Journal	Date
Prazosin		Nightmare-focused interventions and suicide prevention: clarifying the role of imagery rehearsal therapy and prazosin.	Sleep
Prazosin		Prazosin-Related Reductions in Daily Craving Mediate Treatment-Related Daily Alcohol Use Outcomes in Alcohol Use Disorder.	Biological psychiatry global open science
Prazosin		Predicting pHmax and Salt Disproportionation Risk for Basic Drugs.	Molecular pharmaceutics
Prazosin		Prazosin Monotherapy for Adolescent Posttraumatic Stress Disorder: A Case Report and Narrative Review.	Focus (American Psychiatric Publishing)